Cargando…

Effect of the Hypoxia Inducible Factor on Sorafenib Resistance of Hepatocellular Carcinoma

Sorafenib a multi-target tyrosine kinase inhibitor, is the first-line drug for treating advanced hepatocellular carcinoma (HCC). Mechanistically, it suppresses tumor angiogenesis, cell proliferation and promotes apoptosis. Although sorafenib effectively prolongs median survival rates of patients wit...

Descripción completa

Detalles Bibliográficos
Autores principales: Zeng, Zhi, Lu, Qiliang, Liu, Yang, Zhao, Junjun, Zhang, Qian, Hu, Linjun, Shi, Zhan, Tu, Yifeng, Xiao, Zunqiang, Xu, Qiuran, Huang, Dongsheng
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8292964/
https://www.ncbi.nlm.nih.gov/pubmed/34307125
http://dx.doi.org/10.3389/fonc.2021.641522
_version_ 1783724929612513280
author Zeng, Zhi
Lu, Qiliang
Liu, Yang
Zhao, Junjun
Zhang, Qian
Hu, Linjun
Shi, Zhan
Tu, Yifeng
Xiao, Zunqiang
Xu, Qiuran
Huang, Dongsheng
author_facet Zeng, Zhi
Lu, Qiliang
Liu, Yang
Zhao, Junjun
Zhang, Qian
Hu, Linjun
Shi, Zhan
Tu, Yifeng
Xiao, Zunqiang
Xu, Qiuran
Huang, Dongsheng
author_sort Zeng, Zhi
collection PubMed
description Sorafenib a multi-target tyrosine kinase inhibitor, is the first-line drug for treating advanced hepatocellular carcinoma (HCC). Mechanistically, it suppresses tumor angiogenesis, cell proliferation and promotes apoptosis. Although sorafenib effectively prolongs median survival rates of patients with advanced HCC, its efficacy is limited by drug resistance in some patients. In HCC, this resistance is attributed to multiple complex mechanisms. Previous clinical data has shown that HIFs expression is a predictor of poor prognosis, with further evidence demonstrating that a combination of sorafenib and HIFs-targeted therapy or HIFs inhibitors can overcome HCC sorafenib resistance. Here, we describe the molecular mechanism underlying sorafenib resistance in HCC patients, and highlight the impact of hypoxia microenvironment on sorafenib resistance.
format Online
Article
Text
id pubmed-8292964
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-82929642021-07-22 Effect of the Hypoxia Inducible Factor on Sorafenib Resistance of Hepatocellular Carcinoma Zeng, Zhi Lu, Qiliang Liu, Yang Zhao, Junjun Zhang, Qian Hu, Linjun Shi, Zhan Tu, Yifeng Xiao, Zunqiang Xu, Qiuran Huang, Dongsheng Front Oncol Oncology Sorafenib a multi-target tyrosine kinase inhibitor, is the first-line drug for treating advanced hepatocellular carcinoma (HCC). Mechanistically, it suppresses tumor angiogenesis, cell proliferation and promotes apoptosis. Although sorafenib effectively prolongs median survival rates of patients with advanced HCC, its efficacy is limited by drug resistance in some patients. In HCC, this resistance is attributed to multiple complex mechanisms. Previous clinical data has shown that HIFs expression is a predictor of poor prognosis, with further evidence demonstrating that a combination of sorafenib and HIFs-targeted therapy or HIFs inhibitors can overcome HCC sorafenib resistance. Here, we describe the molecular mechanism underlying sorafenib resistance in HCC patients, and highlight the impact of hypoxia microenvironment on sorafenib resistance. Frontiers Media S.A. 2021-07-07 /pmc/articles/PMC8292964/ /pubmed/34307125 http://dx.doi.org/10.3389/fonc.2021.641522 Text en Copyright © 2021 Zeng, Lu, Liu, Zhao, Zhang, Hu, Shi, Tu, Xiao, Xu and Huang https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Oncology
Zeng, Zhi
Lu, Qiliang
Liu, Yang
Zhao, Junjun
Zhang, Qian
Hu, Linjun
Shi, Zhan
Tu, Yifeng
Xiao, Zunqiang
Xu, Qiuran
Huang, Dongsheng
Effect of the Hypoxia Inducible Factor on Sorafenib Resistance of Hepatocellular Carcinoma
title Effect of the Hypoxia Inducible Factor on Sorafenib Resistance of Hepatocellular Carcinoma
title_full Effect of the Hypoxia Inducible Factor on Sorafenib Resistance of Hepatocellular Carcinoma
title_fullStr Effect of the Hypoxia Inducible Factor on Sorafenib Resistance of Hepatocellular Carcinoma
title_full_unstemmed Effect of the Hypoxia Inducible Factor on Sorafenib Resistance of Hepatocellular Carcinoma
title_short Effect of the Hypoxia Inducible Factor on Sorafenib Resistance of Hepatocellular Carcinoma
title_sort effect of the hypoxia inducible factor on sorafenib resistance of hepatocellular carcinoma
topic Oncology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8292964/
https://www.ncbi.nlm.nih.gov/pubmed/34307125
http://dx.doi.org/10.3389/fonc.2021.641522
work_keys_str_mv AT zengzhi effectofthehypoxiainduciblefactoronsorafenibresistanceofhepatocellularcarcinoma
AT luqiliang effectofthehypoxiainduciblefactoronsorafenibresistanceofhepatocellularcarcinoma
AT liuyang effectofthehypoxiainduciblefactoronsorafenibresistanceofhepatocellularcarcinoma
AT zhaojunjun effectofthehypoxiainduciblefactoronsorafenibresistanceofhepatocellularcarcinoma
AT zhangqian effectofthehypoxiainduciblefactoronsorafenibresistanceofhepatocellularcarcinoma
AT hulinjun effectofthehypoxiainduciblefactoronsorafenibresistanceofhepatocellularcarcinoma
AT shizhan effectofthehypoxiainduciblefactoronsorafenibresistanceofhepatocellularcarcinoma
AT tuyifeng effectofthehypoxiainduciblefactoronsorafenibresistanceofhepatocellularcarcinoma
AT xiaozunqiang effectofthehypoxiainduciblefactoronsorafenibresistanceofhepatocellularcarcinoma
AT xuqiuran effectofthehypoxiainduciblefactoronsorafenibresistanceofhepatocellularcarcinoma
AT huangdongsheng effectofthehypoxiainduciblefactoronsorafenibresistanceofhepatocellularcarcinoma